^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + SNS-301 (Immunostimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)
Published date:
11/09/2020
Excerpt:
SNS-301 is delivered intradermally in addition to pembrolizumab in up to 30 patients with locally advanced unresectable or metastatic/recurrent SCCHN….Of seven patients eligible for efficacy analysis, one patient with PD-L1 negative disease had a partial response with a reduction of 29% at week 6 with deepening of the response to 43% at week 12...
DOI:
http://dx.doi.org/10.1136/jitc-2020-SITC2020.0349
